Click Therapeutics™

Smartphones are becoming treatment devices. From chronic pain to mental health, Software-Enhanced Drug™ Therapies are reshaping care. Our CEO, David Klein, joined @Medidata's “from Dreamers to Disruptors” to share how Click is advancing this future: medidata.com/en/from-dreame…

Our abstract “Combining Digital Therapeutics with Neuroplasticity-Inducing Agents: A Framework Modeled on MAT” was accepted for #ISCTM 2025! This framework pairs PDTs with neuroplasticity-inducing agents to standardize care. Learn more on @ISCTM: isctm.org

The next breakthroughs in migraine care won’t be pills. In @MedCityNews, Click CMO Shaheen Lakhan discusses how digital tools like Click's CT-132 – a PTD for the preventive treatment of episodic migraine – are transforming treatment. Read more: medcitynews.com/2025/08/the-ne…

In partnership with @Boehringer Ingelheim, Click Therapeutics is proud to share that CT-155 has met the primary endpoint in the CONVOKE Study, marking a positive step forward for patients suffering from negative symptoms of schizophrenia. Learn more: clicktherapeutics.com/news/boehringe…

ICYMI: Click Therapeutics leadership sat down with @Medidata on July 24 for an in-depth discussion on what the next frontier of patient care looks like. One key takeaway: Personalization through digitization is key. Missed the conversation? Watch here: medidata.com/en/click-webin…

We’re heading to #BIO2025! Join Click at Booth 3678 where our team will be on-site and available for meetings to explore strategic partnerships across PDTs and Software-Enhanced Drug™ therapies. Looking to connect? Contact bd@clicktherapeutics.com

Click will be at #ASCO25, where our CMO Shaheen Lakhan, MD, PhD, FAAN will present our innovative oncology research. Visit us at Booth #13093, and reach out to bd@clicktherapeutics.com to request a meeting. Learn more: meetings.asco.org/meetings/2025-… @ASCO

CT-132, Click’s prescription digital therapeutic for migraine prevention, was featured in @neurology_live with insights from Eric Baron, DO of Cleveland Clinic. He shares how this FDA-authorized, app-based treatment can complement existing therapies: neurologylive.com/view/eric-baro…

Is tech friend or foe to our brains? It depends how we use it. In @Medscape, our CMO Shaheen Lakhan shares insights on how digital tools can erode or nourish cognitive health. At Click, we build treatments that turn tech into a tool for good. Read more: medscape.com/viewarticle/di…

We’re proud to share that our Founder and CEO, David Klein, is a finalist for @EY_US Entrepreneur Of The Year New York! This honor recognizes David’s commitment to innovation and his impact on the future of patient care. Congrats to all the finalists! ey.com/en_us/entrepre…

Click will present Phase 3 data from the ReMMiD-C bridging study of CT-132 at the @ahsheadache 2025 Annual Scientific Meeting on Saturday, June 21 at 9:10 AM CST. Cassandra Snipes, PhD, will present abstract IOR-05. Learn more: ahsam25.eventscribe.net/fsPopup.asp?Pr… #AHSAM

CT-132, the first prescription digital therapeutic for the preventive treatment of episodic migraine in patients 18 years of age and older, has received FDA marketing authorization. Learn more: clicktherapeutics.com/news/click-the…

Click was honored to present a poster at the AAN annual meeting on the effectiveness and safety of our first-in-class investigational PDT for the preventive treatment of episodic migraine. Read more at: medscape.com/viewarticle/fi… #AANAM #AAN2025

Click Therapeutics Founder & CEO, David Benshoof Klein, delivered a keynote address at Medidata NEXT in London last week, where Click announced closing its Series C investment round, provided entirely by @Dassault3DS . Read more here: clicktherapeutics.com/news/click-the…

BREAKING NEWS: @Dassault3DS and Medidata have made a strategic investment in @Click_Tx. 25 years ago we revolutionized clinical trials. Today, we’re expanding the boundaries of healthcare by combining cutting-edge science with the power of software to develop new, cutting-edge patient solutions. Learn more: mdso.io/zck

Today, @Dassault3DS @Medidata announced a strategic investment in Click, having provided the entire Series C funding round. The collaboration will provide a clear path to best-in-class PDTs and Software-Enhanced Drugs™ product approvals. Learn more: medidata.com/en/about-us/ne…

@DrShaheenLakhan , CMO of Click, will be speaking at the 8th Annual #DTxWest in San Diego, CA. On Thursday, March 13, at 9:10 AM PT, Dr. Lakhan will deliver a Keynote Case Study: How Software-Enhanced Drugs Will Change the Future of Care. Register now: dtxglobalsummit.com/west/program

@DrShaheenLakhan, Brett Colbert, and Derek Dykxhoorn recently penned an article for @FrontiersIn Psychiatry on the “Prescription Digital Therapeutics in Psychiatry.” Read it here: frontiersin.org/journals/psych…

Click Therapeutics Founder and Chief Executive Officer David Benshoof Klein shared his predictions for the pharma industry in 2025 in Healthcare IT Today. To learn more on David's insights for the new year, read the full article at: healthcareittoday.com/2025/01/03/pha…

In his latest article for @medcitynews , our CMO Shaheen Lakhan explores how smartphones and social media contribute to a growing mental health crisis - and how the same technology that poses risks can also offer transformative health benefits. Learn more: medcitynews.com/2024/12/the-sa…